EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk

Kelsey Coziahr iD, Austin M Wheeler iD, Brent A Luedders iD, Michael Duryee, Halie Frideres iD, Katherine D Wysham iD, Grant W Cannon iD, Gary Kunkel, Dana P Ascherman iD, Paul A Monach iD, Gail S Kerr iD, Andreas M Reimold und 5 weitere

Arthritis Care & Research · 2025

DOI: 10.1002/acr.70008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Kelsey Coziahr und 16 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Lung Diseases, Interstitial, Matrix Metalloproteinase 7. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase (MMP)‐7, and serum anti‐malondialdehyde‐acetaldehyde (anti‐MAA) antibody for RA‐associated interstitial lung disease risk stratification.

Methods

Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three biomarker score (range 0‐3) was calculated based on the presence of MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors.

Results

Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male, mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (aOR 12.21 [3.82, 38.97] for score of 3 vs. 0). A score ≥1 had 76.1% sensitivity, but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (aHR 4.36 [1.55, 12.27]). Area under the curve for prevalent RA‐ILD and Harrel's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score.

Conclusion

This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. While this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidLung Diseases, InterstitialMatrix Metalloproteinase 7AgedFemaleHumansMaleMiddle AgedAutoantibodiesBiomarkersCross-Sectional StudiesPredictive Value of TestsPrevalenceRisk AssessmentRisk FactorsUnited States

Substanzen

AutoantibodiesBiomarkersMatrix Metalloproteinase 7

Autor:innen und Institutionen

  • Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha.
  • University of Nebraska Medical Center, Omaha.
  • VA Puget Sound Health Care System, Seattle, Washington.
  • University of Washington, Seattle.
  • Salt Lake City VA Health Care System, Salt Lake City, Utah.
  • University of Utah, Salt Lake City.

ORCID-Profile: Kelsey Coziahr, Austin M Wheeler, Brent A Luedders, Halie Frideres, Katherine D Wysham, Grant W Cannon, Dana P Ascherman, Paul A Monach, Gail S Kerr, Ted R Mikuls, Bryant R England

Förderung

  • CSRD VA
  • NIH HHS
  • BLRD VA
  • U.S. Department of Veterans Affairs
  • U.S. Department of Defense
  • NIGMS NIH HHS
  • Rheumatology Research Foundation

Zitieren

APA

Coziahr, K., Wheeler, A. M., Luedders, B. A., Duryee, M., Frideres, H., Wysham, K. D., Cannon, G. W., Kunkel, G., Ascherman, D. P., Monach, P. A., Kerr, G. S., Reimold, A. M., Matson, S. M., Baker, J. F., Thiele, G. M., Mikuls, T. R., & England, B. R. (2025). Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk. Arthritis Care & Research. https://doi.org/10.1002/acr.70008

Vancouver

Coziahr K, Wheeler AM, Luedders BA, Duryee M, Frideres H, Wysham KD, et al. Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk. Arthritis Care & Research. 2025. doi:10.1002/acr.70008

BibTeX
@article{Coziahr2025,
  author = {Coziahr, Kelsey and Wheeler, Austin M and Luedders, Brent A and Duryee, Michael and Frideres, Halie and Wysham, Katherine D and Cannon, Grant W and Kunkel, Gary and Ascherman, Dana P and Monach, Paul A and Kerr, Gail S and Reimold, Andreas M and Matson, Scott M and Baker, Joshua F and Thiele, Geoffrey M and Mikuls, Ted R and England, Bryant R},
  title = {Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.70008}
}
Kostenlos starten →